

### Online Supplementary Material

Pardo G, Pineda ED, Ng CD, Sheinson D, Bonine NG. The association between persistence and adherence to disease-modifying therapies and healthcare resource utilization and costs in patients with multiple sclerosis. *JHEOR*. 2022;9(1):111-116. [doi:10.36469/jheor.2022.33288](https://doi.org/10.36469/jheor.2022.33288)

#### **Table S1: Characterization of MS Symptoms by ICD-9 or ICD-10 Codes**

#### **Figure S1: Patient Attrition Flowchart**

#### **Figure S2: (A) Unadjusted All-Cause Non-DMT Costs Stratified by HCRU Type in Persistent vs Nonpersistent Patients at 12 and 24 Months; (B) Unadjusted MS-Related Non-DMT Costs Stratified by HCRU Type in Persistent vs Nonpersistent Patients at 12 and 24 Months**

#### **Figure S3: (A) Unadjusted All-Cause Non-DMT Costs Stratified by HCRU Type in Adherent vs Nonadherent Patients at 12 and 24 Months; (B) Unadjusted MS-Related Non-DMT Costs Stratified by HCRU Type in Adherent vs Nonadherent Patients at 12 and 24 Months**


This supplementary material has been provided by the authors to give readers additional information about their work.



**Table S1.** Characterization of MS Symptoms by ICD-9 or ICD-10 Codes


MS Symptom	ICD-9/ICD-10 Codes
Other causes of myelitis	ICD-9: 323.82; ICD-10: G04.89
Demyelinating disease of central nervous system	ICD-9: 341.9; ICD-10: G36.9, G37.9
Disorders of optic nerve and visual pathways	ICD-9: 377.3, 377.49; ICD-10: H46
Neurogenic bladder NOS	ICD-9: 596.54; ICD-10: N31.9
Other disorders of soft tissues: neuralgia, neuritis, and radiculitis, unspecified	ICD-9: 729.2; ICD-10: M79.2, M54.10, M54.18
General symptoms: dizziness and giddiness	ICD-9: 780.4; ICD-10: R42
General symptoms: fatigue and malaise	ICD-9: 780.71, 780.79; ICD-10: R53.0, R53.1, R53.81-R53.83, G93.3

Abbreviations: ICD, *International Classification of Diseases, Ninth/Tenth Revision*; MS, multiple sclerosis; NOS, not otherwise specified.

**Figure S1.** Patient Attrition Flowchart


Abbreviations: DMT, disease-modifying therapy; IV, intravenous; MS, multiple sclerosis; NDC, National Drug Code.

**Figure S2. (A)** Unadjusted All-Cause Non-DMT Costs Stratified by HCRU Type in Persistent vs Nonpersistent Patients at 12 and 24 Months; **(B)** Unadjusted MS-Related Non-DMT Costs Stratified by HCRU Type in Persistent vs Nonpersistent Patients at 12 and 24 Months



Abbreviations: DMT, disease-modifying therapy; HCRU, healthcare resource utilization; MS, multiple sclerosis.

**Figure S3. (A)** Unadjusted All-Cause Non-DMT Costs Stratified by HCRU Type in Adherent vs Nonadherent Patients at 12 and 24 Months; **(B)** Unadjusted MS-Related Non-DMT Costs Stratified by HCRU Type in Adherent vs Nonadherent Patients at 12 and 24 Months



Abbreviations: DMT, disease-modifying therapy; MS, multiple sclerosis.